Pooled data from the PULSAR and STELLAR trials were used for this study, published on December 5, 2024 on the The Journal of Heart and Lung Transplantation, which compared effects of the activin signaling inhibitor sotatercept (Winrevair) across pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI).
The analysis evaluated 429 participants divided into subgroups based on cardiac index (CI). Sotatercept demonstrated consistent efficacy across all CI subgroups in improving key clinical outcomes:
- Median 6-minute walk distance
- Pulmonary vascular resistance
- Pulmonary and right atrial pressures
- Right ventricular size
- N-terminal pro-B-type natriuretic peptide levels
Sotatercept also delayed time to death or worsening events in participants with CI ≥2.5 (HR 0.12), ≥2.0 (HR 0.13), and <2.5 (HR 0.21); all p<0.001.
Improvements in World Health Organization (WHO) functional class (all p<0.050) and European Society of Cardiology/European Respiratory Society risk score (all p<0.001) were seen within each subgroup.
These results indicate that sotatercept provides substantial clinical and functional benefits for pulmonary arterial hypertension patients, regardless of baseline cardiac Index levels..
Read more at this link on the Journal of Heart and Lung Transplantation web page
Citation
Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR, The Journal of Heart and Lung Transplantation, December 5, 2024, Mardi Gomberg-Maitland, MD MSca, David B. Badesch, MDb ∙ J. Simon R. Gibbs, MD FRCPc, Ekkehard Grünig, MDd ∙ Marius M. Hoeper, MDe ∙ Marc Humbert, MD PhDf ∙ Grzegorz Kopeć, MD PhDg,h ∙ Vallerie V. McLaughlin, MD FACC FAHAi ∙ Gisela Meyer, MDj ∙ Karen M. Olsson, MDe ∙ Ioana R. Preston, MDk ∙ Stephan Rosenkranz, MDl ∙ Rogerio Souza, MD PhDm ∙ Aaron B. Waxman, MD PhDn ∙ Loïc Perchenet, PhDo ∙ James Strait, MD PhDo ∙ Aiwen Xing, PhDo ∙ Amy O. Johnson-Levonas, PhDo ∙ Alexandra G. Cornell, MD MCRo ∙ Janethe de Oliveira Pena, MD PhDo ∙ H. Ardeschir Ghofrani, MD DOI: 10.1016/j.healun.2024.11.037
